News
Oxford Nanopore Technologies and bioMérieux have announced the launch of AmPORE-TB, a Research Use Only (RUO) solution for the rapid characterization of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis complex, using Oxford Nanopore sequencing technology.
Swipe to discover more
-
Third-Quarter 2025 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2025. Consolidated sales amounted to €2,992 million for the first nine months of 2025 versus €2,871 million for the prior-year period, representing a growth of +4.2% as reported. -
"Always consider sepsis in the context of infection."
Patient associations across the globe are actively engaged in promoting this critical message to both healthcare professionals and the broader public. We met with Dr Rafael Moraes from ILAS, Melissa Mead from The UK Sepsis Trust and Thomas Heymann from Sepsis Alliance to learn more about their actions. -
bioMérieux publishes a Bioethics Charter: A first in the diagnostics sector
bioMérieux confirms its ethical commitment to clinical research through a Bioethics Charter that guarantees transparency, accountability, and respect for human dignity. In particular, it aims to protect research participants when collecting and using biological samples and personal data.
Enabling Decision-Making
- BIOMÉRIEUX ESHOP
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- BIOMÉRIEUX ESHOP
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19